share_log

T2 Biosystems | 8-K: Agreement of Debt Conversion Into Equity

T2 Biosystems | 8-K: Agreement of Debt Conversion Into Equity

T2 Biosystems | 8-K：定期贷款转股权协议
美股sec公告 ·  04/18 16:17
Moomoo AI 已提取核心信息
On April 12, 2024, T2 Biosystems, Inc., a Delaware-incorporated company, reported entering into a significant transaction involving the issuance of equity to settle outstanding loans. The company issued 3,280,618 shares of Common Stock and 17,160.48 shares of Series A Convertible Preferred Stock to a group of lenders led by CRG Partners III L.P. and its affiliates in exchange for the cancellation of $15.0 million in loans. This transaction was part of a Securities Purchase Agreement dated February 15, 2024. Concurrently, T2 Biosystems entered into a Consent and Amendment No. 10 to its Term Loan Agreement, which included the lenders' consent to the equity issuance and an extension of the interest payment period on the term loans. The shares issued in this transaction were not registered under the Securities Act of 1933, as the sale was made to accredited investors and relied on exemptions from registration requirements. Additionally, the company filed a Certificate of Designation with the State of Delaware, detailing the rights and preferences of the Series A Convertible Preferred Stock, including conversion rights, dividend entitlements, and liquidation participation.
On April 12, 2024, T2 Biosystems, Inc., a Delaware-incorporated company, reported entering into a significant transaction involving the issuance of equity to settle outstanding loans. The company issued 3,280,618 shares of Common Stock and 17,160.48 shares of Series A Convertible Preferred Stock to a group of lenders led by CRG Partners III L.P. and its affiliates in exchange for the cancellation of $15.0 million in loans. This transaction was part of a Securities Purchase Agreement dated February 15, 2024. Concurrently, T2 Biosystems entered into a Consent and Amendment No. 10 to its Term Loan Agreement, which included the lenders' consent to the equity issuance and an extension of the interest payment period on the term loans. The shares issued in this transaction were not registered under the Securities Act of 1933, as the sale was made to accredited investors and relied on exemptions from registration requirements. Additionally, the company filed a Certificate of Designation with the State of Delaware, detailing the rights and preferences of the Series A Convertible Preferred Stock, including conversion rights, dividend entitlements, and liquidation participation.
2024年4月12日，特拉华州注册成立的公司T2 Biosystems, Inc. 报告说，已达成一项重大交易，涉及发行股权以结清未偿贷款。该公司向由CRG Partners III L.P. 及其附属公司牵头的一组贷款机构发行了3,280,618股普通股和17,160.48股A系列可转换优先股，以换取取消1,500万美元的贷款。该交易是2024年2月15日证券购买协议的一部分。同时，T2 Biosystems签署了其定期贷款协议的第10号同意和修正案，其中包括贷款人同意股票发行和延长定期贷款的利息支付期限。本次交易中发行的股票未根据1933年《证券法》进行注册，因为此次出售是向合格投资者进行的，并且依赖于注册要求的豁免。此外，该公司还向特拉华州提交了指定证书，详细说明了A系列可转换优先股的权利和优先权，包括转换权、股息权和清算参与权。
2024年4月12日，特拉华州注册成立的公司T2 Biosystems, Inc. 报告说，已达成一项重大交易，涉及发行股权以结清未偿贷款。该公司向由CRG Partners III L.P. 及其附属公司牵头的一组贷款机构发行了3,280,618股普通股和17,160.48股A系列可转换优先股，以换取取消1,500万美元的贷款。该交易是2024年2月15日证券购买协议的一部分。同时，T2 Biosystems签署了其定期贷款协议的第10号同意和修正案，其中包括贷款人同意股票发行和延长定期贷款的利息支付期限。本次交易中发行的股票未根据1933年《证券法》进行注册，因为此次出售是向合格投资者进行的，并且依赖于注册要求的豁免。此外，该公司还向特拉华州提交了指定证书，详细说明了A系列可转换优先股的权利和优先权，包括转换权、股息权和清算参与权。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息